Introduction
Patients with severe hemophilia have undetectable FVIII or FIX levels resulting in spontaneous and trauma related bleeding, especially in the joints. Repeat joint bleeding eventually leads to a crippling arthropathy. Severe hemophilia is rare, with a prevalence of about 40 per million inhabitants. Since its introduction in 1958 by Professor Nilsson in Sweden, 1 many long-term observational studies [2] [3] [4] [5] and two pediatric randomized controlled trials (RCTs) 6, 7 have shown that prophylactic replacement therapy in severe hemophilia prevents bleeds and subsequent hemophilic arthropathy. This was confirmed by the latest version of the Cochrane review on prophylaxis. 8 However, the increased use of factor concentrates in prophylaxis and associated costs (from € 72 000 (USD 76 700) annually for small children 9 to €146 000 (USD 155 600) for an adult 10 on high-dose prophylaxis in the 1990s) have been a limiting factor of a more widespread introduction of prophylaxis.
The Swedish regimen originally aimed at maintaining minimum trough levels of clotting factor activity by using doses of 25-40 IU/kg three times a week for hemophilia A. 11 In the Netherlands however, prophylaxis was introduced in 1968, 12 is important to assess the incremental gains of high-dose prophylaxis.
Assessment of long-term effects requires decades of follow-up and the number of patients with hemophilia is limited. 15 Comparing birth cohorts from centres in two countries provides the best alternative to a randomized controlled trial to assess long-term outcomes of the The aim of the present study was to compare long-term outcomes and costs between the Dutch intermediate-dose and the Swedish high-dose prophylactic regimen for persons with severe hemophilia with a follow-up of up to three decades. As optimal dosing for For personal use only. on April 9, 2017. by guest www.bloodjournal.org From prophylaxis has never been established, this study provides a unique insight which could not have been reported previously.
Methods

Design and setting
The study was designed as an observational study comparing two cohorts using retrospective assessment of treatment and prospective assessment of outcome. The study was performed at the hemophilia treatment centres of the University Medical Center 
Patients
All patients with severe hemophilia (FVIII/IX < 1% or <1 IU/dl), born between 1-1-1970 and 1-1-1994, treated at the participating centres, with life-long access to care and treatment data available were eligible for this study. Patients with a history of inhibitors (any inhibitor activity > 0.6 BU with decreased recovery) were excluded. Assessments were performed during regular outpatient visits. Patients aged 18 years and older were considered as adults. Informed consent was obtained from all patients prior to participation.
Patient characteristics and treatment history
Baseline patient characteristics registered included: date of birth, date of diagnosis, type of hemophilia, hepatitis C-and HIV status, and date of first joint bleed.
To assess treatment history, date of first treatment, start of home treatment, onset of prophylaxis, as well as complete history of prophylactic regimens used were collected. In addition, orthopaedic surgical procedures (including arthroscopies and radioactive synovectomies) were extracted from patient files.
Current treatment
For the last 5 years before evaluation, annual clotting factor consumption was extracted from patient logs and hospital pharmacy records. In addition, number of visits to the center and details on hospital admissions were documented.
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Outcome
The primary outcome parameter was clinical joint status, assessed by the center's physiotherapist, using the Haemophilia Joint Health Score (HJHS version 1.0). 16, 17 The HJHS is based on physical examination of elbows, knees, and ankles (max 20-26 points per joint) and observation of gait for knees and ankles (0-4 points). The total score was calculated without adding overall global gait to the individual joint scores resulting in a total score ranging from 0, signifying perfect joint health, to 144. The HJHS score was originally developed to assess subtle joint damage in children with hemophilia. The score was used for this study because the items scored are not age-specific and differences in outcome were expected to be small. All HJHS scores were performed by one physiotherapist at each participating center. Standardisation and reliability was established during a training session (January 2006, 12 patients, intra-class correlation (ICC) 0.84) with all three designated physiotherapists. 18 Secondary outcome parameters were the annual number of joint bleeds, self reported activities, health-related quality of life and social participation.The annual number of jointand soft tissue bleeds over the last five years was extracted from the patient logs, medical files, and hospital databases by research nurses at each center. Bleeds were defined as any complaint requiring treatment with clotting factor concentrate. Bleeds located in shoulders, elbows, wrists, hips, knees, or ankles were considered as joint bleeds. All data were entered in an electronic case report form (eCRF) using predefined definitions. To minimise bias, all definitions and how to complete the eCRF were documented and discussed prior to the study start.
Questionnaires were administered to adult patients only. Self-reported limitations in activities were assessed using the Haemophilia Activities List (HAL), [20] [21] ,while physical activity levels were assessed by the International Physical Activity Questionnaire (IPAQ). 22 Health related quality of life expressed as utility was assessed using the EQ-5D. 23 EQ-5D utility values were calculated using the Dutch tariff 24 for both cohorts.
To compare social participation, data on achieved level of education and labour market participation were collected and compared to the age-matched general male population in the respective countries using the Labor Force Survey at Statistics Netherlands 25 and Statistics Sweden, 26 respectively; and the Swedish Registration of Education. 27 For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
Cost and resource use
Dutch prices for the year 2010 were collected for evaluation of health care resource use and lost production in both cohorts. Prices were based on national price lists 28,29 and academic hospital prices from 2011 for surgeries (Table 1) . Days lost from work were valued according to the human capital approach. 30 Costs were translated to USD using the European Central Bank 2010 bilateral average annual exchange rate: 1 Euro=1.3257 USD (http://sdw.ecb.europa.eu).
Direct medical costs (factor concentrate costs and other costs) and indirect costs (cost of days lost from work) for the five-year evaluation period were compared between cohorts.
In addition, life-long use of factor concentrates according to age and treatment strategy was estimated from individual-level data on history of prescribed prophylacic regimens and body weight for Swedish patients and from an earlier study for Dutch patients. 31 Factor consumption according to age and treatment strategy were also compared graphically.
Statistics
Students' T-tests, non-parametrical Mann-Whitney U tests, and chi-squared tests were used to compare patient characteristics and outcomes according to treatment strategy.
Panel data population-averaged generalised linear regression was used to predict the average annual cost of a mean-weight adult patient for each treatment regimen. Both logistic analysis (dependent HJHS ≥ 10) and generealized linear models (GLM, dependent HJHS, gamma distribution, log link) were used to study the effects of age at start of prophylaxis, independent of country, age at evaluation, and 5-year factor consumption.
Statistical analyses were performed using SPSS version 20 (Armonk, NY: IBM Corp.) and
Stata version12 (College Station, TX: StataCorp LP).
Results
Patients 78 Dutch (intermediate-dose) and 50 Swedish (high-dose) patients were assessed during regular outpatient visits. The overall inclusion rate was 128/156 (78%); including 78/92 (85%) of Dutch patients (eight refusals, five unable to include due to irregular visits, and one patient not invited as he was currently taking interferon) and 50/71 (70%) of Swedish eligible patients (21 refusals).
To assess the impact of excluded patients on the overall study population we compared age, previous orthopedic surgeries and treatment with clotting factor concentrate during the last five years between excluded and included patients for both countries. Dutch excluded patients (n=14) were significantly older (mean age 32.3 vs 24.9 years, p<0.01), but had a similar history of previous orthopaedic surgery (21% vs 15%, p= 0.69); excluded patients showed a trend towards using full prophylaxis less often (64% vs 78%, p=0.31) and a 23% lower annual clotting factor consumption (mean 1680 IU/kg/yr, mean difference 500 IU/kg/yr,p=0.06). Swedish excluded patients (n=21) had a similar age (25.9 vs 23.8 years,p=0.24) and history of orthopaedic surgery (5 vs 8%, p=1.0), but also a trend towards using full prophylaxis less often (76% vs 86%, p=0.15) and a 21% lower annual clotting factor consumption (mean 3240 IU/kg/yr, mean difference 865 IU/kg/yr, p=0.03)
The majority of included patients were adults at the time of evaluation: (NL 62/78, 79%; SE 41/50, 82%). The number of patients with available data according to outcome parameter is shown in Figure 1 .
Patient characteristics & treatment
The mean age of included patients was 24.5 years (range .The majority (115/128; 90%) of patients had hemophilia A . Overall, 34% of patients were hepatitis C positive and 5% were HIV positive. Although the prevalence of HIV was similar, Hepatitis C infection was more common in Dutch patients (42% vs 22%, p=0.04).
Patient characteristics and treatment according to prophylactic regimen are shown in Table 2 . Patients were diagnosed with severe hemophilia early in life in both countries 
Clinical outcome
Clinical outcome according to regimen is shown in Table For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
Quality of life
The quality of life measured by EQ-5D utility was high (Table 3) The response rate was lower for Dutch patients (76% vs 83%, Fig 1) but this is not expected to have affected outcome, as non-responders and responders had similar age, education and employment, as well as joint status.
Social participation
The achieved level of education and labor force participation rates for adult patients are shown in Table 4 . At evaluation, a higher percentage of Swedish participants reported having completed university education, but the differences in overall educational achievement were not significant. Compared to the general male population, fewer had achieved a university degree at evaluation, although this may result from some still being students and national statistics not including the youngest adults (the Netherlands age 25+ years, Sweden 20+ years). 25, 27 Among employed participants, full-time employment dominated: 38/43 (88%) of Dutch and 26/30 (87%) of Swedish patients were working full-time. Few patients were unemployed (the Netherlands 2, Sweden 4) and the unemployment rates among participants were similar (the Netherlands) or lower (Sweden) than those of their peers.
Overall, 86% of patients on either regimen did not report any days lost from work or school due to hemophilia during the five-year study period. Among patients who reported missing days from work or education on a short-or long-term basis, the median number of days lost during the five year period for Dutch patients (n=11) was 202 (IQR 39-536), compared to 28 (IQR 3-39) for Swedish patients (n=7). This large difference was driven by five Dutch patients: three undergoing interferon-based treatment for HCV infection and could not work for on average 7.7 months, and two who were disabled on a long-term basis, one after an intracranial bleed and another for severe arthropathy, HIV and HCV infection.
Costs
The mean and median 5-year treatment costs in 1000 USD per patient according to prophylactic regimen and Dutch prices are shown in A clinically and statistically significant difference in factor concentrate use between the two prophylactic regimens was also seen in a 30-years perspective (p<0.01 all ages , Figure 2 ).
Absolute differences in median annual factor use increased with age: ranging from around 50 000 IU/yr before school age, to 100 000 IU/yr at age 15, and 150 000 IU/yr at age 20- 
Study design
To analyse the long-term outcomes of prophylactic treatment regimens, we used a combination of state-of-the-art prospective outcome assessment 34 and collection of retrospective data from patient files. Use of routinely documented data enabled extraction of bleeding and full treatment history; questionnaires were validated and every effort was undertaken to standardize joint assessment. Similar to a randomized controlled trial, the prophylactic regimen was allocated based on study group (i.e.country of birth) and not on clinical characteristics or ability to pay for treatment. The study aimed to compare 'full' birth cohorts to avoid selection bias. Key treatment characteristics of non-participants were analyzed. In both countries, non-participants showed a trend towards less intensive treatment with a lower annual consumption of factor concentrates (intermediate-dose regimen -23%; high-dose regimen -21%). This implies that results of this study slightly overestimated annual total costs but it is unlikely to have biased the results of the costcomparison. The effects on outcome cannot be estimated: non-participants may have a milder bleeding pattern and/or a lower adherence to prophylaxis.
While it is common to report clinical results separately for hemophilia A and B, this distinction may be less important for the aim of this paper. As expected, the differences between prophylactic regimens was consistent when restricting the analysis to persons with haemophilia A only (see the Supplemental Data link at the top of the online article).
Comparison with other studies:
Earlier studies have covered long-term clinical outcomes of prophylactic treatment of Dutch and Swedish cohorts. 3, 5 A previous retrospective comparison of Dutch and Swedish adolescent patients, lacking formal outcome assessment and collection of cost data, observed statistically significant differences in joint outcome among patients younger than 15 years only. 35 Other studies concern comparisons of high-dose prophylaxis to ondemand treatment in young patients aged up to 6 6 and 11 7 years, respectively. The lack of long-term controlled studies was recently considered as an important limitation of economic evaluations. 36 When considering the incremental cost of providing life-long prophylaxis instead of on demand treatment there are very few data available. So far, only two studies have presented cost data in unselected cohorts of severe hemophilia patients treated on demand. At price levels of year 2000, mean direct medical costs of 79 000 EUR/yr (73 000 USD) were reported in France 37 and 52 000 EUR/yr (48 000 USD) in Norway. 10 Quality of life was not measured in these studies. Currently, the Hemophilia Utilization Group Study (HUGS part Va) are collecting cost data in the USA. 38 It is evident that on-demand treatment is much less costly than the prophylactic regimens presented in this study.
However, the long-term outcome of on-demand treatment is worse in terms of joint status, serious haemorrhages, quality of life and labor force participation. 4, 37, 39 Previous health-economic evaluations have addressed issues of cost-effectiveness in haemophilia care 9, 40 and one cost-benefit analysis in a Swedish setting reported that the average willingness to pay for prophylaxis in the general population exceeded the average cost of provision of prophylaxis per taxpayer. 41 This study does not contain a formal economic evaluation as the cost differences were nearly USD 159 000 per year and the difference in utility was not statistically significant in these data. Using five year data the cost per bleed avoided would be USD 120 600. Therefore, any cost-utility analysis on these data will show that compared to intermediate dose prophylaxis, general provision of highdose prophylaxis will not be cost-effective at current prices and cost-effectiveness thresholds (e.g. 80 000 EUR or 106 056 USD per QALY in the Netherlands).
Clinical implications
This study shows a statistically significant but small incremental benefit after nearly doubling the annual prophylactic dose. The benefit was observed in all outcome parameters, except quality of life. This may reflect the limited clinical effects of one additional joint bleed per year, or the inability of the generic EQ-5D questionnaire to pick up small differences. From a life-long perspective, it is expected that differences in outcome between these two cohorts will have increased in another 20 years. However, we do not know the extent nor the clinical implications of such an increase.
Is the difference attributable to dose difference only? One of the drivers of the slightly better outcome in the high-dose group may be the earlier start of prophylaxis. This is well established, 42, 43 and both countries have started prophylaxis earlier over the last decades. 2, 3 Regression analyses failed to identify a statistically significant and independent effect of age at start of prophylaxis in outcome. This unexpected finding may be due to two limitations in the present data: lack of variation and limited power. Lack of variation was present in the Swedish data: all patients started prophylaxis very early. Power was limited by small differences in outcome and limited patient numbers.
Currently, prophylactic dosing is mostly based on the Swedish regimen of 25-40 IU/kg per infusion and dosages used in pediatric trials have been consistently high: 25 IU/kg thrice weekly or every other day, i.e. 3900 and 4550 IU/kg/yr, respectively. 6, 7 For older patients, guidelines on dosing are unavailable, 44, 45 and the recommendation is to just keep this dose, 45 in spite of the fact that adults have more regulated activity patterns, a longer FVIII half-life, and a weaker association between trough levels and bleeding. 46, 47 For clinical practice, it will always be important to prevent bleeding, especially in joints.
Overall, these favorable results support the need for an early start of prophylaxis and continuing this treatment in adults with severe hemophilia. At patient level, the data on joint outcome suggest that a proportion of patients are equally well-off with intermediate-dose
prophylaxis while others need a high-dose regimen to control their bleeding. In the absence of valid laboratory paramaters to assess a patients' phenotype, clinical parameters of bleeding frequency and physical activities, combined with pharmacokinetic information 48 are the only tools available to individualize prophylactic dosing. Eventually, some adult patients even discontinued prophylaxis without experiencing frequent bleeding, as was observed in these cohorts, but also in others. 49 In conclusion, this first direct comparison of two prophylactic regimens suggest that at group level, a more intensive and higher dosed regimen may provide slightly improved outcome at a significant cost increase. At patient level, the challenge is to identify patients who will be as well-off on lower doses without compromising patient safety. Even in small patient groups such as these, improving cost effectiveness of treatment should be considered.
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